Skip to main content
. 2019 Apr 5;13:1087–1098. doi: 10.2147/DDDT.S198003

Table 2.

Tumor inhibition ratios (mean ± SD, n=3)

Formulations DOX/ELE Hyd NLCs DOX/ELE NLCs DOX Hyd NLCs ELE Hyd NLCs DOX/ELE INJ
Tumor inhibition ratios (%) 82.9±3.7 65.4±3.2 61.9±4.1 46.7±2.6 24.1±2.1

Abbreviations: DOX/ELE Hyd NLCs, doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers; INJ, injection.